Organic Pharmaceutical Excipients Global Market Report 2024

The organic pharmaceutical excipients market has grown strongly in recent years. It will grow from $10.36 billion in 2023 to $11.38 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth observed in the historical period can be attributed to several factors, including heightened demand for drug formulations, improved patient acceptance and compliance, adherence to quality and safety standards, innovations in drug delivery methods, and the necessity to meet regulatory compliance requirements. These combined elements have contributed significantly to the expansion seen during that period.

The organic pharmaceutical excipients market is expected to see strong growth in the next few years. It will grow to $16.07 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%. The anticipated growth in the forecast period is linked to several key factors, notably the increased prominence of biopharmaceuticals and biosimilars, a growing preference for natural and sustainable ingredients, heightened focus on personalized medicine, the emergence of novel therapies, and the global expansion of pharmaceutical production.

The growth trajectory of the organic pharmaceutical excipients market is set to surge owing to the escalating demand for pharmaceutical drugs. These drugs, essential for preventing, diagnosing, and treating various medical conditions, are driving the need for compatible organic pharmaceutical excipients to facilitate effective drug formulations. Notably, in June 2022, the European Federation of Pharmaceutical Industries and Associations reported a 4.6% increase in global pharmaceuticals production in 2021, highlighting North America's dominance in global pharmaceutical sales. This surge in demand for pharmaceutical drugs is a primary catalyst behind the organic pharmaceutical excipients market's expansion.

The organic pharmaceutical excipients market is anticipated to witness substantial growth propelled by the burgeoning healthcare expenditure. This increase in spending, as indicated by the 2021-2030 National Health Expenditure report from the Centers for Medicare & Medicaid Services, underscores heightened investment in research and development within the pharmaceutical sector. Such investments lead to the creation of novel drugs, driving the demand for sophisticated organic pharmaceutical excipients. Projections indicate an annual 5.1% growth in national health spending, reaching nearly $6.8 trillion by 2030, with Medicare and Medicaid spending also on an upward trajectory. This surge in healthcare expenditure directly fuels the organic pharmaceutical excipients market's expansion.

A prominent trend gaining traction is the utilization of label-friendly excipients for nutritional products. Companies are emphasizing the integration of label-friendly excipients into nutritional product formulations to cater to evolving consumer preferences for clean labeling in the nutraceutical industry. An example is Colorcon's April 2023 launch of Nutracore, a line of label-friendly excipients tailored for nutraceutical and supplement providers. Crafted from natural and organic materials, Nutracore meets consumers' demands for clean labeling while ensuring optimal product performance, meeting both consumer expectations and manufacturing needs.

Major players in the organic pharmaceutical excipients market are innovating with advanced technologies, such as excipient technologies, to expand their consumer base and boost revenue. For instance, Lubrizol Life Science (LLS) Health's May 2022 introduction of Apisolex Technology showcases a unique solubility-enhancing excipient designed for parenteral drug products. Apisolex effectively addresses solubility challenges, enhancing solubility by up to 50,000-fold and enabling high drug loading. This technology, particularly impactful in oncology treatments via direct bloodstream injection, circumvents limitations associated with oral delivery methods, revolutionizing the development of parenteral drug products. This strategic innovation is indicative of the industry's drive toward advanced excipient technologies to meet evolving market demands.

In September 2022, Roquette, a renowned France-based producer of plant-based pharmaceutical excipients, completed the acquisition of Crest Cellulose Pvt. Ltd., an India-based manufacturer specializing in cellulose-based excipients for pharmaceuticals and food ingredients. The undisclosed acquisition amount reflects Roquette's strategic move to enhance its offerings by integrating Crest Cellulose's expertise. This acquisition aligns with Roquette's commitment to providing pharmacopeia-compliant, premium-grade, and meticulously traceable solutions that effectively tackle intricate challenges in drug delivery within the pharmaceutical industry.

Major companies operating in the organic pharmaceutical excipients market report are Roquette Frères SA, DuPont de Nemours Inc., Ashland Inc., Badische Anilin- und Sodafabrik, Kerry Group plc, Evonik Industries AG, Croda International plc, The Lubrizol Corporation, Innophos Holdings Inc., Wacker Chemie AG, Merck KGaA, Colorcon Asia Private Limited, Rochem International Inc., Eastman Chemical Company, JRS PHARMA GMBH + CO KG, Cargill Incorporated, Ingredion Incorporated, Sensient Technologies Corporation, Internatio-Müller Chemical Distribution, Lonza Group Ltd., DFE PHARMA INDIA PRIVATE LIMITED., Omya AG, Sigachi Industries Pvt. Ltd., Meggle AG, Associated British Foods plc, Archer Daniels Midland Company, Food Machinery & Chemical Corporation, Innospec Inc., Mitsubishi Chemical Corporation, International Flavors & Fragrances Inc.

North America was the largest region in the global organic pharmaceutical excipients market in 2023. The regions covered in the organic pharmaceutical excipients market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the organic pharmaceutical excipients market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of organic pharmaceutical excipients are oleochemicals, carbohydrates, petrochemicals, proteins, and other compounds. Oleochemicals, derived from oils and fats, find application across various products such as soaps, detergents, cosmetics, lubricants, and biodiesel. In pharmaceutical formulations, they serve diverse purposes such as binding agents, coating agents, colorants, disintegrants, and other functionalities within oral, topical, parenteral, and other formulations.

The organic pharmaceutical excipients research report provides organic pharmaceutical excipients market statistics, including the organic pharmaceutical excipients industry's global market size, regional shares, competitors with an organic pharmaceutical excipients market share, detailed organic pharmaceutical excipients market segments, market trends and opportunities, and any further data you may need to thrive in the organic pharmaceutical excipients industry. This organic pharmaceutical excipients market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The organic pharmaceutical excipient market consists of sales of starch, cellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.